| Literature DB >> 29080978 |
Leila Abar1, Ana Rita Vieira2, Dagfinn Aune2, Jakub G Sobiecki2, Snieguole Vingeliene2, Elli Polemiti2, Christophe Stevens2, Darren C Greenwood3, Doris S M Chan2, Sabrina Schlesinger2, Teresa Norat2.
Abstract
PURPOSE: There is no published dose-response meta-analysis on the association between height and colorectal cancer risk (CRC) by sex and anatomical sub-site. We conducted a meta-analysis of prospective studies on the association between height and CRC risk with subgroup analysis and updated evidence on the association between body fatness and CRC risk.Entities:
Keywords: BMI; Colorectal cancer; Continuous update project; Height; Meta-analysis
Mesh:
Year: 2017 PMID: 29080978 PMCID: PMC6060816 DOI: 10.1007/s00394-017-1557-1
Source DB: PubMed Journal: Eur J Nutr ISSN: 1436-6207 Impact factor: 5.614
Fig. 1Flowchart of study selection
Fig. 2Height and colorectal cancer risk (dose–response and nonlinear analysis). RR relative risk, 95% CI 95% confidence interval. Summary RR calculated using a random-effects model
Summary of results
| Height, per 5 cm | ||||
|---|---|---|---|---|
|
| RR (95% CI) |
|
| |
| Colorectal cancer | ||||
| All studies | 14 | 1.04 (1.02–1.05) | 91 | < 0.001 |
| Stratified by sex | ||||
| Men | 8 | 1.04 (1.03–1.05) | 0 | 0.46 |
| Women | 10 | 1.04 (1.02–1.05) | 91.5 | < 0.001 |
| Stratified by geographic location | ||||
| Europe | 6 | 1.03 (1.00–1.07) | 95.6 | < 0.001 |
| North America | 7 | 1.06 (1.01–1.11) | 79.7 | < 0.001 |
| Asia | 1 | 1.03 (0.95–1.10) | – | – |
| Australia | – | – | – | – |
| Duration of follow-up | ||||
| < 10 years follow-up | 4 | 1.06 (1.04–1.08) | 0 | 0.75 |
| 10–< 15 years follow-up | 5 | 1.05 (1.00–1.11) | 83.9 | < 0.001 |
| ≥ 15 years follow-up | 5 | 1.03 (1.00–1.07) | 94.3 | < 0.001 |
| Assessment of height | ||||
| Measured | 6 | 1.05 (1.04–1.06) | 0 | 0.47 |
| Self-reported | 8 | 1.01 (1.00–1.02) | 68.8 | 0.002 |
| Number of cases | ||||
| Cases < 1000 | 7 | 1.05 (1.00–1.09) | 0 | 0.58 |
| Cases 1000–3000 | 4 | 1.04 (1.00–1.09) | 87 | < 0.001 |
| Cases ≥ 3000 | 3 | 1.04 (1.00–1.08) | 98 | < 0.001 |
| Colon cancer | ||||
| All studies | 14 | 1.02 (1.02–1.03) | 87 | < 0.001 |
| Stratified by sex | ||||
| Men | 9 | 1.02 (1.01–1.04) | 75.3 | < 0.001 |
| Women | 12 | 1.02 (1.01–1.03) | 85.7 | < 0.001 |
| Stratified by geographic location | ||||
| Europe | 5 | 1.01 (1.00–1.02) | 86 | < 0.001 |
| North America | 6 | 1.05 (1.01–1.10) | 89.7 | < 0.001 |
| Asia | 2 | 1.12 (0.96–1.32) | 79.2 | 0.03 |
| Australia | 1 | 1.13 (1.04–1.23) | – | – |
| Proximal colon cancer | ||||
| All studies | 4 | 1.02 (0.99–1.05) | 76.1 | < 0.01 |
| Stratified by sex | ||||
| Men | 2 | 1.12 (0.90–1.40) | 78.6 | 0.03 |
| Women | 4 | 1.01 (0.99–1.03) | 52.3 | 0.09 |
| Stratified by geographic location | ||||
| Europe | 1 | 1.03 (0.96–1.11) | 0 | 0.60 |
| North America | 2 | 1.01 (1.00–1.01) | 0 | 0.82 |
| Asia | – | – | – | – |
| Australia | 1 | 1.24 (1.11–1.39) | 0 | 0.74 |
| Distal colon cancer | ||||
| All studies | 4 | 1.01 (1.00–1.01) | 0 | 0.85 |
| Stratified by sex | ||||
| Men | 2 | 1.05 (0.92–1.19) | 45.5 | 0.17 |
| Women | 4 | 1.01 (1.00–1.02) | 16.9 | 0.31 |
| Stratified by geographic location | ||||
| Europe | 1 | 1.05 (0.94–1.17) | ||
| North America | 2 | 1.01 (1.00–1.01) | 0 | 0.58 |
| Asia | – | – | – | – |
| Australia | 1 | 1.04 (0.87–1.24) | ||
| Rectal cancer | ||||
| All studies | 14 | 1.01 (1.00–1.02) | 61.7 | 0.002 |
| Stratified by sex | ||||
| Men | 10 | 1.02 (1.00–1.05) | 39.7 | 0.09 |
| Women | 12 | 1.01 (1.00–1.01) | 57.8 | 0.006 |
| Stratified by geographic location | ||||
| Europe | 6 | 1.00 (1.00–1.01) | 37.0 | 0.16 |
| North America | 5 | 1.06 (1.02–1.10) | 28.5 | 0.24 |
| Asia | 2 | 1.04 (1.00–1.09) | 0 | 0.61 |
| Australia | – | – | – | – |
RR relative risk; 95% CI 95% confidence interval
Fig. 3Weight and colorectal cancer risk (dose–response and nonlinear analysis). RR relative risk, 95% CI 95% confidence interval. Summary RR calculated using a random-effects model
Fig. 4BMI and colorectal cancer risk (dose–response and nonlinear analysis). RR relative risk, 95% CI 95% confidence interval. Summary RR calculated using a random-effects model
Fig. 5Waist circumference and colorectal cancer risk (dose–response analysis). RR relative risk, 95% CI 95% confidence interval. Summary RR calculated using a random-effects model
Fig. 6Waist-to-hip ratio and colorectal cancer risk (dose–response and nonlinear analysis). RR relative risk, 95% CI 95% confidence interval. Summary RR calculated using a random-effects model